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ABSTRACT
Background: We aimed to analyze the frequency and distribution of PD-L1 
expression in specimens from prostate cancer (PC) patients using two different anti-
PD-L1 antibodies (E1L3N, SP263).
Materials and Methods: PD-L1 immunohistochemistry was performed in a tissue 
microarray consisting of 82 castration-resistant prostate cancer (CRPC) specimens, 
70 benign prostate hyperplasia (BPH) specimens, 96 localized PC cases, and 3 PC cell 
lines, using two different antibodies (clones E1L3N, and SP263). Staining images for 
CD4, CD8, PD-L1, and PanCK of a single PD-L1 positive case were compared, using a 
newly developed dot-wise correlation method for digital images to objectively test 
for co-expression.
Results: Depending on the antibody used, in tumor cells (TC) only five (E1L3N: 
6%) and three (SP263: 3.7%) samples were positive. In infiltrating immune cells 
(IC) 12 (SP263: 14.6%) and 8 (E1L3N: 9.9%) specimens showed PD-L1 expression. 
Two PC cell lines (PC3, LnCaP) also displayed membranous immunoreactivity. All 
localized PCs or BPH samples tested were negative. Dot-wise digital correlation of 
expression patterns revealed a moderate positive correlation between PD-L1 and 
PanCK expression, whereas both PanCK and PD-L1 showed a weak negative Pearson 
correlation coefficient between CD4 and CD8.
Conclusions: PD-L1 was not expressed in localized PC or BPH, and was only found 
in a minority of CRPC tumors and infiltrating immune cells. Protein expression maps 
and systematic dot-wise comparison could be a useful objective way to describe the 
relationship between immuno- and tumor-related proteins in the future, without the 
need to develop multiplex staining methods.
INTRODUCTION
The therapeutic options for castration-resistant 
prostate cancer (CRPC) have increased dramatically 
in the past years. Recent clinical trials have led to the 
FDA approval of cabazitaxel [1], abiraterone [2–4], 
enzalutamide [5, 6], radium-223 [7], and Sipuleucel-T 
[8]. Nevertheless, most CRPC patients develop resistance 
to these new agents, making it of utmost importance to 
develop newer treatment strategies [9]. The objective 
responses to immunotherapy in other cancers are driving 
renewed enthusiasm for cancer immunotherapy, however, 
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the role of immunotherapy in CRPC is yet to be fully 
elucidated [10].
Programmed Death Receptor 1 (PD-1, or CD279), 
a member of the extended family of T cell regulators, is 
expressed on the surface of activated T cells, B cells, and 
macrophages [12]. Its ligand, Programmed Death Receptor 
Ligand 1 (PD-L1, or B7-H1 or CD274), is expressed on 
tumor cells, macrophages, T cells and certain other cell 
types [12], and the interaction of these two molecules 
negatively regulates immune responses. Of major interest 
is that inhibition of the interaction between PD1 and PD-
L1 can enhance T-cell responses in vitro, and mediates 
clinical anti-tumor activity [13–20]. A correlation between 
PD-L1 expression on tumor or immune cells in the tumor 
specimen and tumor response to anti-PD1 or anti-PD-L1 
immunotherapy has been described in various advanced 
tumors [13–21]. PD-L1 is expressed  in a wide range of 
tumors, at a frequency of up to 88% in some types of cancer 
[22]. In the tumor microenvironment, PD-L1 expressed on 
tumor cells binds to PD-1 on activated T cells that have 
migrated to the tumor. This delivers an inhibitory signal 
to those T cells, preventing them from killing target tumor 
cells, and protecting the tumor from immune elimination 
[22].  Recently, in a small study with ten CRPC patients 
treated with pembrolizumab, response in three patients has 
been reported [23]. Tumor tissue was available for two 
of these three patients, and showed PD-L1 expression. 
In addition, primary and metastatic CRPC showed robust 
synergistic responses when immune checkpoint blockade 
was combined with myeloid-derived suppressor cells 
(MDSC)-targeted therapy. Mechanistically, combination 
therapy efficacy stemmed from the upregulation of 
interleukin-1 receptor antagonist and suppression of 
MDSC-promoting cytokines secreted by prostate cancer 
cells. These recent observations by Lu et al. illuminate a 
new treatment concept, combining immune checkpoint 
blockade with MDSC-targeted therapies for mCRPC [11].
The first aim of this study was to systematically 
describe the expression of PD-L1 in benign prostatic 
hyperplasia (BPH), localized prostate cancer (PC), and 
CRPC using two anti-PD-L1 antibodies. The second aim 
was to observe if PD-L1 status was dependent on previous 
treatment modalities. The third aim was to develop a new 
method to describe the relationship between immune 
cells and tumor-related proteins using pseudo-colored 
protein expression maps, and to use dot-wise correlation 
coefficients of superimposed images as an objective co-
location measurement.
RESULTS
Expression of PD-L1 in benign and malignant 
prostate tissue
This study included 248 tissue samples (70 BPH, 
96 PC, 82 CRPC) and 3 PC cell lines. There was no 
expression of PD-L1 observed in either BPH or localized 
PC samples (0%). Examples of PD-L1 tumor cell (TC) 
and immune cell (IC) staining in CRCP specimens 
and cell lines (clone SP263 and E1L3N) are given in 
Figure 1A–1F. Of the three tested paraffin embedded 
cell cultures (E1L3N), only PC3 and LnCaP showed 
membranous PD-L1 expression. A comparison of 
staining patterns and scoring was performed on serial 
sections of tissue microarrays with CRPC samples 
(Figure 2A–2B). Two antibody clones were used for 
PD-L1 immunohistochemistry assays (E1L3N, SP263). 
Overall, PD-L1 expression patterns were similar in both 
assays, and CRPC samples displayed heterogeneous PD-
L1 expression. As illustrated in Figure 2B, clone SP263 
showed the strongest membranous staining in tumor cells. 
However, with clone SP263, only three of 82 analyzable 
cases showed membranous immunoreactivity in more 
than 1% of tumor cells (3.7%), whereas clone E1L3N 
revealed 5 positive out of 81 analyzable CRCP samples 
(6.0%). Figure 3A displays the direct expression values 
(% positive tumor cells) by using clone E1L3N versus 
SP263. The comparison of PD-L1 expression (%) with 
clone SP263 versus E1L3N showed significant correlation 
coefficients (Figure 3B and 3C). No significant association 
of PD-L1 immunoreactivity with expression of phospho-
ERK1/2 (Figure 4A and 4D), phospho-mTOR (Figure 4B 
and 4E), phospho-4E-BP1 (Figure 4C and 4F), and Ki-67 
proliferation fraction (data not shown) could be observed, 
after correction for multiple testing (Figure 4A–4F).
PD-L1 status and previous treatment modalities
 In CRPC samples, expression of PD-L1 (E1L3N) 
was present in 5 of 81 (6%) cases. All five positive 
specimens were retrieved by palliative transurethral 
resection of the prostate (TURP), and no PD-L1 expression 
was found in bone (n = 10), brain (n = 1), lung (n = 1), or 
lymph node (n = 1) metastases (Supplementary Table 1). 
Co-localization experiments using clone E1L3N
 Immunohistochemistry revealed co-localization 
of PD-L1 and PanCK in tumor areas, whereas stroma 
containing CD4 and CD8 positive lymphocytes was 
predominantly located surrounding the tumor tissue 
(Figure 5). This was confirmed by dot-wise correlation 
showing a moderate positive Pearson correlation 
coefficient for PD-L1 and PanCK expression (r = 0.51). 
In addition there were weak negative Pearson correlation 
coefficients for PanCK and CD4 (r =–0.26) and CD8 (r = 
–0.28), and for PD-L1 and CD4 (r =–0.05) and CD8 (r = 
–0.20) expression (Figure 6).
DISCUSSION
In the present study, we observed no PD-L1 
expression in BPH or localized PC, and only limited 
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expression on CRPC TCs and ICs, comparing two 
different PD-L1 antibodies. We did not observe any 
association between PD-L1 and previous treatment 
modalities. We demonstrated how protein expression 
maps and dot-wise comparison could be a useful objective 
measurement to describe the relationship between immune 
cells and tumor-related proteins. 
Our findings regarding PD-L1 expression are only 
partially consistent and extend those from prior reports. 
PD-L1 expression seems to be an important biomarker 
as it has been associated with biochemical recurrence 
in PC [24], and overall survival in other cancers [25]. 
Furthermore, clinical trials have suggested that tissue 
expression of PD-L1 might be predictive for therapy 
response to PD-1 and PD-L1 immunotherapy [12, 14–
19, 26–28]. The expression of PD-L1 observed in this 
study is slightly lower compared to previously published 
advanced PC [29] and CRPC cohorts (15% and 19% 
PD-L1 expression respectively) [30], and is distinct to a 
radical prostatectomy cohort (52.5% PD-L1 expression) 
[24]. These contradictory results in PD-L1 expression can 
be explained by different antibodies and scoring methods. 
Our scoring methods and compared antibodies are in line 
with recently accepted methodologies and guidelines for 
non-small cell lung cancer [31] and are currently regarded 
a common standard for PD-L1 testing. 
Several PD-L1 immunohistochemistry assays with 
custom reagents and scoring systems have been developed 
in parallel, therefore, studies reporting PD-L1 expression 
and its value as a biomarker cannot be compared 
accurately. Whereas the heterogeneous methodologies 
are addressed by first harmonization studies for lung 
cancer [32], there is no consensus regarding preferred 
assay or scoring systems for PC. According to our results, 
we finally implemented the SP263 antibody for PD-L1 
staining at our institution due to its satisfactory staining 
Figure 1: (A–F) Programmed death ligand 1 (PD-L1) scoring criteria and examples of tumor cell (TC) and immune cell (IC) staining in 
CRCP specimens and cell lines (clone SP263 and E1L3N). A: negative PD-L1 immunoreactivity in a CRCP specimen. B: PD-L1 staining 
in >1% of immune cells in a CRPC sample. C: PD-L1 expression in >30% of immune cells.. D: PD-L1 expression in > 5% of tumor cells. 
E, F: staining of PD-L1 in formalin-fixed paraffin-embedded PC3 (E) and LnCaP (F) cell culture pellets. Diameter of tissue microarray 
spot 0.6 mm. Inserts and cell line images, original magnification 400x. Scoring criteria of PD-L1 immunohistochemistry according to Spira 
et al. [43].
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Figure 2: Comparison of PD-L1 staining results for two different monoclonal anti-PD-L1 antibodies using tissue microarrays of CRPC 
specimens (panel (A) E1L3N, panel (B) SP263). Single tissue spots have a diameter of 0.6 mm. Zoomed versions, showing positive 
membranous PD-L1 immunoreactivity in a positive CRCP patient (dashed circle).
Figure 3: Direct comparison of anti-PD-L1 antibodies E1L3N and SP263. (A) Direct expression values (% positive tumor 
cells) for clone E1L3N (green) and SP263 (red). (B and C) Scatter plots for the comparison of immunoreactivity in % (clones E1L3N, 
SP263) regarding tumor cells (3B) and immune cells (3C).
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properties. To improve the described interobserver 
variability of the different PD-L1 scoring methods 
[32], digital pathology and protein maps using dot-wise 
comparison might be a useful tool for pathologists.
The scarce expression of PD-L1 in our CPRC 
cohort is consistent with the results of several clinical 
trials, which showed no PD-L1 expression in specimens 
retrieved before starting anti-PD-L1 treatment [14, 
18, 33–35]. However, recently a small cohort of ten 
CRPC patients treated with pembrolizumab has been 
published, whereby three patients showed response to 
pembrolizumab [22]. In two of these three patients, tumor 
tissue was available and showed PD-L1 expression using 
the same antibody as in the present study (E1L3N). The 
authors described that both samples showed a pronounced 
leukocyte infiltration. Of note is the fact that the lymph 
node metastasis showed PD-L1 expression in cancer cells 
(cytokeratin positive), whereas in the liver metastases, 
PD-L1 expression was found in the infiltrating leukocytes. 
This early phase II trial [22], along with our results, stress 
the potential influence of the tumor microenvironment 
regarding treatment response. Ongoing clinical studies 
with immunotherapeutic agents in men with CRPC [36] 
are expected to report PD-L1 expression in pre-therapy 
specimens, and will hopefully allow for the establishment 
of harmonized methodologies to assess relevant features.
As PD-L1 expression in other tumor types  shows 
variability at various time points [37], a major question 
remains if there is a therapeutic window for the optimal 
timing of immunotherapy, and if PD-L1 expression and 
response to immunotherapy is associated with previous 
treatment modalities (e.g. androgen deprivation, radio-, or 
chemotherapy). The observation in our study that no case 
after radiotherapy expressed PD-L1 is consistent with a 
study by Bernstein et al., who showed that treating cell lines 
with radiotherapy resulted in a decrease in the expression 
of PD-L1 [38]. Even though radiation therapy seems to 
decrease PD-L1 expression in this study, there might still 
be a role for radiotherapy. Further studies with optimal 
fractionation schemes may be able to induce an immune-
stimulatory activity. A thorough understanding of the 
molecular mechanisms of immune checkpoint regulation 
will help to make use of this biological knowledge, and to 
design therapies or combinations with established agents.
Figures 4: Cumulative bar charts showing the association of PD-L1 immunoreactivity with the expression of phospho-
ERK1/2, phospho-mTOR, and phospho-4E-BP1.
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These data must be interpreted in the context of 
the study design. First, although we have analyzed a 
large cohort, this is a retrospective analysis and there is a 
potential selection bias. Second, it is difficult to compare 
the results from our study with previous work due to 
different methodologies used to evaluate PD-L1 expression. 
Nevertheless, the positive staining in the included cell lines, 
our previous publication in germ cell tumors [39], and the 
accordance of our two antibodies, which was also observed 
in a harmonization study [32], support our protocol. Third, 
even though we tried to minimize tumor heterogeneity 
using two different cores for each patient in the tissue micro 
arrays (TMA), the real PD-L1 expression might be higher 
because of heterogeneity of PD-L1 expression within 
the tumor. Fourth, the therapeutic landscape has changed 
dramatically in the past years and our cohort was treated 
with only a subset of the current therapeutic options.
MATERIALS AND METHODS
Patients and tissue samples
Clinico-pathological data and follow up 
information on all patients was retrieved from the 
Department of Pathology and Molecular Pathology, 
University Hospital Zurich, and the clinical file of the 
University Hospital Zurich, Switzerland from 2000 
to 2013. The study was approved by the local ethical 
committee (reference number KEK StV. 25-2008). 
All patients were treated in different hospitals with the 
available options: surgical ADT (orchiectomy), chemical 
ADT (LHRH agonists e.g. goserelin, leuprorelin, anti-
androgens (bicalutamide)), chemotherapy (docetaxel) 
or radiotherapy. Inclusion criteria for this retrospective 
analysis required tissue collection during transurethral 
resection of the prostate (TURP), or tumor metastasis 
resection, and rising PSA or clinical progress under 
androgen deprivation therapy. The first TMA included 
78 formalin-fixed paraffin embedded tissue specimens 
of patients, which were sampled after the diagnosis of 
CPRC. Suitable areas for prostate tissue retrieval were 
marked on routine H&E-stained sections. A section of 
the paraffin block, 0.6 mm in diameter, was punched 
out of the suitable area and inserted into the recipient 
block using a tissue arrayer (Beecher Instruments, Inc., 
Sun Prairie, WI, USA). The whole tissue microarray 
preparation was accomplished on the paraffin blocks 
using cores from two different areas of each tumor or 
control tissue to account for tissue heterogeneity. 
The second TMA consisted of BPH samples (n = 
70), localized PC (n = 96), the androgen-resistant human 
PC cell lines (PC3 and DU145) and the androgen-sensitive 
PC cell line (LnCaP). The detailed characteristics of this 
TMA have been reported previously [40]. 
Figure 5: Co-localization experiments using clone E1L3N. Immunohistochemical staining for PanCK, PD-L1, CD4, and CD8 
on serial sections of a PD-L1 positive CRPC sample (upper row). Immunohistochemical stainings were transformed into expression maps, 
using false colors for high (red) to low (blue) protein expression (middle row). Overlay images (lower row) were created displaying PanCK 
as green and PD-L1, CD4, and CD8 proteins as magenta. PD-L1 was co-localized with PanCK positive tumor cell areas but not with 
the surrounding stroma containing CD4- or CD8-positive lymphocytes. Abbreviations: CD4: cluster of differentiation 4; CD8: cluster of 
differentiation 8; CRPC: castration resistant prostate cancer; PanCK: pan cytokeratin; PD-L1: programmed cell death ligand 1.
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Immunohistochemistry
Three-micron-thick sections of TMA blocks and 
formalin-fixed, paraffin-embedded tissues were mounted 
on glass slides (Super-Frost Plus; Menzel, Braunschweig, 
Germany), deparaffinized, rehydrated and stained 
with hematoxylin–eosin using standard histological 
techniques. For immunohistochemical staining of 
both TMA and large sections, the Ventana Benchmark 
automated staining system and Ventana reagents (both 
Ventana Medical Systems, Tucson, AZ, USA) were used. 
After deparaffinization in xylene, slides were rehydrated 
in decreasing concentrations of ethanol. Endogenous 
peroxidase was blocked using the Ventana endogenous 
peroxidase blocking kit after a rinse with distilled 
water. For antigen retrieval, slides were heated with cell 
conditioning solution (CC1, Ventana) according to the 
manufacturer’s instructions.
For the detection of the PD-L1 protein in BPH, PC, 
and cell line specimens, one anti-human PD-L1 rabbit 
monoclonal antibody was used: E1L3N (Cell Signaling 
Technology, Inc., Danvers, MA, USA). For the detection 
of the PD-L1 protein in CRPC, two anti-human PD-
L1 rabbit monoclonal antibodies were used: E1L3N 
(Cell Signaling Technology, Inc., Danvers, MA, USA), 
SP263 (Ventana Medical Systems, Tucson, AZ, USA). 
A multi-tumor TMA and a tonsillectomy specimen were 
used as positive and negative controls to establish the 
staining protocol for the PD-L1 antibodies. A dilution of 
1:1000 resulted in a strong membranous signal without 
non-specific background staining in positive controls 
(squamous epithelium of tonsillectomy specimen). PD-L1 
negative lung cancer cases were used as negative controls. 
For the expression maps, primary antibodies against 
CD4 (clone SP35 pre-diluted, Ventana Medical Systems, 
Tucson, AZ, USA), CD8 (clone C8/114B, 1:100, Dako, 
CA, USA), and PanCK (clone AE1/AE3, 1:50, Dako) were 
applied and adjusted to the Ventana Benchmark system 
after performing titrations. Immunohistochemistry with 
antibodies against Phospho-ERK1/2, Phospho-mTOR, 
Phospho-4E-BP1, and Ki-67 (MIB1) was performed, as 
previously described [41].
An experienced pathologist (PJW) evaluated all 
scanned and digitized tissue microarray spots (Spot 
browser, Alphelys, Plaisir, France). A second independent 
observer (CDF) re-evaluated the TMAs. In discrepant 
cases, the two observers achieved consensus after detailed 
case discussion. Percentages of PD-L1 positive tumor cells 
and the staining pattern were evaluated for each punch. 
PD-L1 expression was recorded if a distinct membranous 
staining signal on the tumor cell surface was observed. In 
analogy to the scoring guidelines for non-small cell lung 
cancer [31] , we used a > 1% cutoff for membranous PD-
L1 positivity in tumor cells.
Generation of expression maps
The staining images for CD4, CD8, PanCK, and 
PD-L1 were aligned, superimposed, and normalized for 
the generation of a pseudo-colored expression map. Whole 
slide images of one case, and of all performed stainings 
were digitized (digital slide scanner NanoZoomer 2.0-HT 
Figure 6: Scatter plots of the co-localization experiments using clone E1L3N. PD-L1 and PanCK expression showed a moderate 
positive Pearson’s correlation coefficient indicating overlapping expression areas (A). The comparison of PD-L1 and PanCK with CD4 
and CD8 immunoreactivity showed negative weak Pearson correlation coefficients, indicating that PD-L1 and PanCK are not expressed 
in the same location as CD4+ or CD8+ lymphocytes (B–E). The x and y axis are represented by (normalized) intensity, ranging from 0 to 
255. Abbreviations: CD4: cluster of differentiation 4; CD8: cluster of differentiation 8; PanCK: pan cytokeratin; PD-L1: programmed cell 
death ligand 1.
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C9600, Hamamatsu Photonics, Solothurn, Switzerland) at 
40x magnification (approximately 2k-3k x 2k-3k pixels 
per image). The images of consecutive tissue slices were 
pre-processed and aligned for dot-wise correspondence in 
four steps. First, the original images were white-balanced 
to remove grayish background. Second, the tissue regions 
were cropped and rotated, translated and rescaled for rigid 
alignment of the consecutive slices to the middle slice. 
The background was then removed to exclude background 
artifacts that could disturb the following finer alignment 
process. Third, to refine the alignment and to address for 
morphological changes of the tissues in consecutive slices, 
we incorporated a non-linear SIFT flow algorithm [42]. For 
SIFT flow, the images were scaled down to half edge size, 
and the standard parameters were used except for a cell size 
of 5 pixels and a top window size of 20 pixels to obtain 
optimal alignment results. Finally, the fully dot-wise aligned 
and downscaled images were then gray-scaled, inverted, 
and independently normalized for intensities between 0 
and 255. The intensity maps were then compared for each 
case using a dot-wise Pearson correlation between the 
pixels of the images. All processes have been implemented 
in MATLAB R2014a. For visualization purposes only, 
the gray-scaled images have been pseudo-colored with 
MATLAB’s jet color map function, assigning blue values 
for low intensities and red values for high intensities.
CONCLUSIONS
In summary, the scarce PD-L1 expression in CRPC 
and absence in localized PC indicates that advanced 
PC patients may have to be selected carefully when 
offered checkpoint inhibition. However, prospective 
clinical trial data is needed. Our results do not confirm 
that PD-L1 expression can be induced by orchiectomy, 
LHRH-agonists, anti-androgens, radiation therapy or 
chemotherapy. Neither did we find an association with 
PD-L1 expression and ERK- or mTOR signaling activity. 
Protein expression maps and dot-wise comparison could 
be a useful objective method to describe the topographical 
relationship between immunological and tumor-related 
proteins, in general.
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